Developer docs
API playgroundTry for free, no card

Search company profiles

Paladin Labs

Full company profile

uuid0038zcw

Namestring
Paladin Labs
Company typeenum
Private
Founded yearint
1996
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMontreal, Canada
HQ citystring
Montreal
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, dermatological treatments, prescription medicines, pharmaceutical distribution, Canadian pharma
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals
Social media profiles1 record
Cost components5 values
Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Paladin Labs is a Canadian specialty pharmaceutical company that researches, develops, acquires, and markets specialty pharmaceutical products, with a focus on dermatological treatments such as Locacorten Vioform and Canthacur, distributed primarily to patients and healthcare providers in Canada.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Locacorten Vioform
No data
Market position
Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Paladin Labs

Specialty Pharmaceuticalspaladin-labs.com

Paladin Labs firmographics

Firmographics
Name
Paladin Labs
Website
https://paladin-labs.com
Company type
Private
Founded year
1996
Headcount range
51–100 employees
Ownership category
akta.pro rank

Where Paladin Labs is headquartered

Location

Headquarters

HQ city
Montreal
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Paladin Labs business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Operations

Paladin Labs product offering

Product offering

Core offering

Paladin Labs is a Canadian specialty pharmaceutical company that researches, develops, acquires, and markets specialty pharmaceutical products, with a focus on dermatological treatments such as Locacorten Vioform and Canthacur, distributed primarily to patients and healthcare providers in Canada.

Differentiator

Problem solved

Functional benefit

Products and services

  • Locacorten Vioform

Companies that use Paladin Labs

Customer profile

Segments1 record

Ideal customer profiles1 record

Paladin Labs technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Paladin Labs competitors and assessment

Company assessment

Market position

Customer concentration

Paladin Labs social profiles

Digital presence

Paladin Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Paladin Labs leadership team

Management profile

Number of profiles

Paladin Labs funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Paladin Labs M&A and investment

M&A and investment

M&A4 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Paladin Labs

What does Paladin Labs do?

Paladin Labs is a Canadian specialty pharmaceutical company that researches, develops, acquires, and markets specialty pharmaceutical products, with a focus on dermatological treatments such as Locacorten Vioform and Canthacur, distributed primarily to patients and healthcare providers in Canada.

When was Paladin Labs founded?

Paladin Labs was founded in 1996. It employs 51 to 100 people.

Where is Paladin Labs based?

Paladin Labs is headquartered in Montreal, Canada, in the North America region.

Does Paladin Labs have an API?

No public API is recorded for Paladin Labs.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Yahoo3 Top Healthcare Sector Stocks for Canadian Investors in 2025The article recommends three TSX healthcare stocks for Canadian investors in 2025, detailing Knight Therapeutics and Kneat.com. Knight Therapeutics plans to acquire Paladin Labs for $100 million plus $20 million, adding $70 million in annual revenue. Kneat.com reported 40% revenue growth to $13.7 million in Q4 2024.NewswirePaladin Labs Announced Favourable CADTH Recommendation for XCOPRI™ (cenobamate tablets)Paladin Labs announced that CADTH recommended public reimbursement for XCOPRI (cenobamate) as adjunctive therapy for partial-onset seizures in adults with epilepsy. The recommendation follows Health Canada's June 12, 2023 approval. Paladin Labs will negotiate with federal, provincial, and territorial payers to secure access.PR NewswireEndo Announces Approval of XCOPRI™ (cenobamate tablets) in CanadaEndo International plc announced that its operating company, Paladin Labs Inc., received regulatory approval from Health Canada for XCOPRI (cenobamate tablets) to treat partial-onset seizures in adults. The drug, which was discovered and developed by SK Biopharmaceuticals, is scheduled for a market launch in December 2023. This approval expands the commercial availability of the anti-seizure medication within the Canadian healthcare system.PR NewswireC3i partners with Paladin Labs Inc. to offer Canadian clinicians a complimentary testing service to detect T315I mutationC3i Center Inc and Paladin Labs Inc. have partnered to launch a complimentary clinical testing program in Canada for detecting the T315I mutation in Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia patients. The program uses digital PCR technology offering approximately 100 times greater sensitivity than Sanger sequencing. Canadian clinicians can request the test for eligible patients who are resistant to tyrosine kinase inhibitor therapy.BenzingaWhy Endo International Stock Is Soaring TodayEndo International Plc stock surged approximately 90% on Tuesday, trading at 73 cents per share, in apparent reaction to the U.S. Supreme Court's decision to overturn the Roe v. Wade ruling that had established constitutional abortion rights for nearly 50 years. The pharmaceutical company's subsidiary Paladin Labs holds brands including Plan-B emergency contraception licensed for the Canadian market. The court's ruling returns authority to regulate abortion to individual states, potentially expanding demand for emergency birth control products.PR NewswireAcute Bacterial Skin and Skin Structure Infections (ABSSSI) Market to Surpass US$ 20,450.6 Million by 2030 - Coherent Market InsightsCoherent Market Insights published a market intelligence report estimating the global acute bacterial skin and skin structure infections (ABSSSI) market will grow from US$ 10,263.5 million in 2022 to US$ 20,450.6 million by 2030, representing a CAGR of 9.0%. Key growth drivers cited include increasing approvals of novel ABSSSI drugs, such as AbbVie's FDA approval of Dalvance for pediatric patients and Paladin Labs' launch of Xydalba in Canada, as well as rising industry consolidation with Advanz Pharma's acquisition of Correvio Pharma in 2020. The report identifies market players increasingly pursuing inorganic growth strategies including partnerships, acquisitions, and collaborations to expand their market presence.NewswirePaladin Labs Announces the Launch of Xydalba® (dalbavancin for injection) in CanadaPaladin Labs announced the launch of Xydalba (dalbavancin for injection) in Canada for adult patients with acute bacterial skin and skin structure infections. The 30-minute IV therapy is available nationwide and was approved by Health Canada in September 2018.news.cision.comIsofol announces licensing agreement for Paladin Labs Inc. to commercialize arfolitixorin in CanadaIsofol announced a definitive license agreement with Endo Ventures, a subsidiary of Endo International, to register and commercialize arfolitixorin in Canada. Endo's Paladin Labs will handle regulatory approval and commercialization, with Isofol receiving up to $23.05 million in upfront, development, regulatory, and sales-based milestone payments plus tiered royalties.PR NewswireInvitation to a conference call and webcast by Isofol in connection with the entered license agreement for Paladin Labs Inc. to commercialize arfolitixorin in CanadaIsofol Medical AB announced a definitive licensing agreement with Endo Ventures Limited, a subsidiary of Endo International plc, granting exclusive rights for the commercialization of arfolitixorin in Canada, with Paladin Labs Inc. designated to seek regulatory approval and manage commercialization activities including distribution, marketing, and pricing. The agreement enables Isofol to leverage Endo's subsidiary infrastructure for market entry of its drug candidate for advanced colorectal cancer. Isofol is inviting investors and analysts to a conference call on November 2, 2020 to discuss the transaction.PR NewswireIsofol announces licensing agreement for Paladin Labs Inc. to commercialize arfolitixorin in CanadaIsofol Medical AB has entered into an exclusive licensing agreement with Endo Ventures Limited, designating Paladin Labs Inc. to seek regulatory approval and commercialize arfolitixorin as a first-line treatment for metastatic colorectal cancer in Canada. Isofol may receive up to $US 23.05 million (SEK 205 million) in upfront, development, regulatory, and sales-based milestone payments, plus tiered royalties on net sales in solid double-digit figures. Isofol will retain all international development rights and remain as the global sponsor of the ongoing Phase III AGENT study, while Paladin will serve as the Market Authorization holder for Canada.